&quot;Pleased to announce our animal data in a severe Crohns model showing dramatic improvement in histopath and less ﬁbrotic progression. ALD-R491 is an oral agent with outstanding safety data, ready for Phase 1. #CrohnsAndColitisAwarenessWeek #IBD&quot;

ALD-R491 - Aluda Pharma

Dec 2, 2022